SpyGlass Pharma, Inc.

SpyGlass Pharma, Inc. is a late-stage biopharmaceutical company specializing in sustained drug delivery solutions for chronic eye conditions, particularly open-angle glaucoma and ocular hypertension. Founded in 2019 by Malik Y. Kahook, M.D., and Glenn Sussman, the company develops innovative platforms that integrate approved medicines like bimatoprost into familiar surgical procedures to provide long-term disease control and vision preservation. Its lead candidate, the BIM-IOL System, combines proprietary drug pads with intraocular lenses for implantation during routine cataract surgery, delivering therapy over three years and addressing treatment gaps in daily eye drops. Additionally, the BIM-DRS targets glaucoma patients not undergoing cataract surgery. Headquartered in Aliso Viejo, California, SpyGlass Pharma employs 65 professionals and is led by CEO Patrick Mooney, with a team boasting deep expertise in ophthalmology, drug delivery, and clinical development. The company's non-bioerodible SpyGlass Platform originated from the University of Colorado Anschutz School of Medicine, positioning it to transform ophthalmic care by reducing patient burden and enhancing outcomes in the healthcare sector.